Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 10
Submit an article Journal homepage
1,480
Views
126
CrossRef citations to date
0
Altmetric
Review

Glycolytic enzyme inhibitors in cancer treatment

Roberto Scatena Catholic University, Department of Laboratory Medicine, Largo A. Gemelli 8, 00168 Rome, Italy +39 0 630 154 222; +39 0 635 501 918; [email protected]
,
Patrizia Bottoni Catholic University, Department of Laboratory Medicine, Largo A. Gemelli 8, 00168 Rome, Italy +39 0 630 154 222; +39 0 635 501 918; [email protected]
,
Alessandro Pontoglio Catholic University, Department of Laboratory Medicine, Largo A. Gemelli 8, 00168 Rome, Italy +39 0 630 154 222; +39 0 635 501 918; [email protected]
,
Lucia Mastrototaro Catholic University, Department of Laboratory Medicine, Largo A. Gemelli 8, 00168 Rome, Italy +39 0 630 154 222; +39 0 635 501 918; [email protected]
&
Bruno Giardina Catholic University, Department of Laboratory Medicine, Largo A. Gemelli 8, 00168 Rome, Italy +39 0 630 154 222; +39 0 635 501 918; [email protected]
Pages 1533-1545 | Published online: 22 Sep 2008

Bibliography

  • Chu E, De Vita VT. Principles of cancer management: chemotherapy. In: De Vita VT, Hellman S, Rosenberg SA, editors, Cancer – principles & practice of oncology. 6th edition. Philadelphia USA. Lippincot Williams and Wilkins; 2001. p. 224-35
  • Verweij J, Nooter K, Stoter G. Principles of chemotherapy. In: Souhami RL, Tannock I, Hohenberger P, Horiot JC, editors, Oxford textbook of oncology. 2nd edition. Oxford University Press; 2002. p. 404-12
  • Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 2004;4:227-35
  • Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63
  • Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9
  • Warburg O. On the origin of cancer cells. Science 1956;123:309-14
  • Hammerman PS, Fox CJ, Thompson CB. Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem Sci 2004;29:586-92
  • Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E. Energy metabolism in tumor cells. FEBS J 2007;274:1393-418
  • Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2007;66:8927-30
  • Garber K. Energy deregulation: licensing tumor to grow. Science 2006;312:1158-9
  • Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005;30:142-50
  • Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005;65:177-85
  • Gottschalk S, Anderson N, Hainz C, et al. Imatinib (STI571) – mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 2004;10:6661-8
  • Costello LC, Franklin RB. ‘Why do tumour cells glycolyse?’: from glycolysis through citrate to lipogenesis. Mol Cell Biochem 2005;280:1-8
  • Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006;18:598-608
  • Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-82
  • Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18:54-61
  • Deberardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20
  • Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316-25
  • Yasuda M, Matsubara J, Yamasaki H, et al. Death-resistant and nonresistant malignant human cell lines under anoxia in vitro. Int J Clin Oncol 2007;12:455-62
  • Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med 2007;85:1301-7
  • Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180-92
  • Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-37
  • Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-46
  • Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 2007;39:267-74
  • Kimura Y, Morita SY, Matsuo M, Ueda K. Mechanism of multi-drug recognition by MDR1/ABCB1. Cancer Sci 2007;98:1303-10
  • Leslie EM, Deeley RG, Cole SP. Multi-drug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216-37
  • Stubbs E, Kraas J, Morton KA, Clark PB. Brain abnormalities detected on whole-body 18F-FDG PET in cancer patients: spectrum of findings. AJR Am J Roentgenol 2007;188:866-73
  • Wienhard K. Measurement of glucose consumption using [(18)F]fluorodeoxyglucose. Methods 2002;27:218-25
  • Van der Hiel B, Pauwels EK, Stokkel MP. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIa. Therapy response monitoring in breast cancer, lymphoma and gliomas. J Cancer Res Clin Oncol 2001;127:269-77
  • Harris RA. Carbohydrate metabolism I: major metabolic pathways and their control. In: David L, Devlin TM, editiors, Textbook of biochemistry with clinical correlations. 6th edition. John Wiley & Sons, Inc. Hoboken, NJ; 2006. p. 581-635
  • Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006;25:4777-86
  • Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006;25:4683-96
  • Le Goffe C, Vallette G, Charrier L, et al. Metabolic control of resistance of human epithelial cells to H2O2 and NO stresses. Biochem J 2002;364:349-59
  • Kurtoglu M, Gao N, Shang J, et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther 2007;6:3049-58
  • Kang HT, Hwang ES. 2-Deoxyglucose: an anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sci 2006;78:1392-9
  • Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol 2002;64:1745-51
  • Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004;53:116-22
  • Maschek G, Savaraj N, Priebe W, et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004;64:31-4
  • Ledoux S, Yang R, Friedlander G, Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 2003;63:7284-90
  • Mohanti BK, Rath GK, Anantha N, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 1996;35:103-11
  • Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005;181:507-14
  • Robey RB, Hong R, Zhong L, et al. Effects of the anti-tumor agent 3-bromopyruvate (3BrPA) on glycolytic energy metabolism. FASEB J 2007;21:890-6
  • Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001;173:83-91
  • Geschwind JF, Ko YH, Torbenson MS, et al. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002;62:3909-13
  • Harrison SA, Di Bisceglie AM. A new approach to therapy for hepatocellular carcinoma? Hepatology 2003;37:471-3
  • Foubister V. Energy blocker to treat liver cancer. Drug Discov Today 2002;7:934-5
  • Ko YH, Smith BL, Wang Y, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004;324:269-75
  • Vali M, Liapi E, Kowalski J, et al. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 2007;18:95-101
  • Chang JM, Chung JW, Jae HJ, et al. Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: in vivo investigation in normal rabbit model. Acad Radiol 2007;14:85-92
  • Shin SW, Han H, Choo SW, et al. Hepatic intra-arterial injection of 3-bromopyruvate in rabbit VX2 tumor. Acta Radiol 2006;47:1036-41
  • Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005;65:613-21
  • Buijs M, Vossen JA, Geschwind JF, et al. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs 2008 [doi: 10.1007/s10637-008-9145-0]
  • Cao X, Bloomston M, Zhang T, et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res 2008;14:1831-9
  • Meng F, Matteucci MD, Har CP. The antiproliferative activity of 3-bromopyruvate is not due to selective inhibition of glycolysis [abstract no. 2714]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12 – 16; San Diego, CA. Philadelphia (PA): AACR; 2008
  • Brawer MK. Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol 2005;7(Suppl 7):S21-6
  • Di Cosimo S, Ferretti G, Papaldo P, et al. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc) 2003;39:157-74
  • Sweetman SC, editor. Martindale: the complete drug reference. 35th edition. Electronic version. Pharmaceutical Press, London; 2005
  • Amadori D, Frassineti GL, De Matteis A, et al. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. Breast Cancer Res Treat 1998;49:209-17
  • De Lena M, Lorusso V, Latorre A, et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer 2001;37:364-8
  • Oudard S, Carpentier A, Banu E, et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2003;63:81-6
  • Oudard S, Miccoli L, Dutrillaux B, Poupon MF. Targeting the gene of glucose metabolism for the treatment of advanced gliomas. Bull Cancer 1998;85:622-6
  • Miccoli L, Poirson-Bichat F, Sureau F, et al. Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment. J Natl Cancer Inst 1998;90:1400-6
  • Sun AQ, Yüksel KU, Jacobson TM, Gracy RW. Isolation and characterization of human glucose-6-phosphate isomerase isoforms containing two different size subunits. Arch Biochem Biophys 1990;283:120-31
  • Funasaka T, Hu H, Hogan V, Raz A. Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence. J Biol Chem 2007;282:36362-9
  • Funasaka T, Hu H, Yanagawa T, et al. Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res 2007;67:4236-43
  • Haga A, Tanaka N, Funasaka T, et al. The autocrine motility factor (AMF) and AMF-receptor combination needs sugar chain recognition ability and interaction using the C-terminal region of AMF. J Mol Biol 2006;358:741-53
  • Tanaka N, Haga A, Naba N, et al. Crystal structures of mouse autocrine motility factor in complex with carbohydrate phosphate inhibitors provide insight into structure-activity relationship of the inhibitors. J Mol Biol 2006;356:312-24
  • Rathmell JC, Fox CJ, Plas DR, et al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003;23:7315-28
  • Bando H, Atsumi T, Nishio T, et al. Phosphorylation of the 6-phosphofructo-2-kinase/fructose2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res 2005;11:5784-92
  • Chesney J. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis. Curr Opin Clin Nutr Metab Care 2006;9:535-9
  • Clem B, Telang S, Clem A, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 2008;7:110-20
  • Marin-Hernandez A, Rodríguez-Enríquez S, Vital-González PA, et al. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 2006;273:1975-88
  • Peng SY, Lai PL, Pan HW, et al. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 2008;19:1045-53
  • Old SE, Landa LE, Mohrenweiser HW. Hominoid triosephosphate isomerase: regulation of expression of the proliferation specific isozyme. Mol Cell Biochem 1989;89:73-85
  • Ismail SA, Park HW. Structural analysis of human liver glyceraldehyde-3-phosphate dehydrogenase. Acta Crystallogr D Biol Crystallogr 2005;61:1508-13
  • Lin SJ, Guarente L. Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol 2003;15:241-6
  • Sundararaj KP, Wood RE, Ponnusamy S, et al. Rapid shortening of telomere length in response to ceramide involves the inhibition of telomere binding activity of nuclear glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 2004;279:6152-62
  • Colell A, Ricci JE, Tait S, et al. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 2007;129:983-97
  • Song S, Finkel T. GAPDH and the search for alternative energy. Nat Cell Biol 2007;9:869-70
  • Saunders PA, Chen RW, Chuang DM. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis. J Neurochem 1999;72:925-32
  • Bressi JC, Verlinde CL, Aronov AM, et al. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J Med Chem 2001;44:2080-93
  • Suresh S, Bressi JC, Kennedy KJ, et al. Conformational changes in Leishmania mexicana glyceraldehyde-3-phosphate dehydrogenase induced by designed inhibitors. J Mol Biol 2001;309:423-35
  • Lai1 JCK, Bhardwaj V, Rizvi N, et al. Glycolytic enzyme inhibitors as novel anti-cancer drugs. The Northwest Regional Meeting; 2007 June 17 – 20; Boise, ID
  • Rodríguez-Enríquez S, Vital-González PA, Flores-Rodríguez FL, et al. Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells. Toxicol Appl Pharmacol 2006;215:208-17
  • Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008;111:5350-8
  • Yoshioka H, Geyer CB, Hornecker JL, et al. In vivo analysis of developmentally and evolutionarily dynamic protein-DNA interactions regulating transcription of the Pgk2 gene during mammalian spermatogenesis. Mol Cell Biol 2007;27:7871-85
  • Duan Z, Lamendola DE, Yusuf RZ, et al. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multi-drug resistance phenotype. Anticancer Res 2002;22:1933-41
  • Chen G, Gharib TG, Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 2003;100:13537-42
  • Narasimhan K, Changqing Z, Choolani M. Ovarian cancer proteomics: Many technologies one goal. Proteomics Clin Appl 2008;2:195-218
  • Thierolf M, Hagmann ML, Pfeffer M, et al. Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker Proteomics Clin Appl 2008;2:11-22
  • Lay AJ, Jiang XM, Kisker O, et al. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 2000;408:869-73
  • Daly EB, Wind T, Jiang XM, et al. Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochim Biophys Acta 2004;1691:17-22
  • Fothergill LA, Herman C, Watson TI. The phosphoglycerate mutases. Adv Enzymol Mol Biol 2006;62:227-13
  • Li C, Xiao Z, Chen Z, et al. Proteome analysis of human lung squamous carcinoma. Proteomics 2006;6:547-58
  • Scatena R, Bottoni P, Giardina B, et al. Modulation of cancer cell line differentiation: a neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer. Proteomics Clin Appl 2008;2:229-37
  • Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005;65:177-85
  • Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 2001;58:902-20
  • Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005;15:300-8
  • García-Alles LF, Erni B. Synthesis of phosphoenol pyruvate (PEP) analogues and evaluation as inhibitors of PEP-utilizing enzymes. Eur J Biochem 2002;269:3226-36
  • Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-6
  • Kolev Y, Uetake H, Takagi Y, Sugihara K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol 2008;15:2336-44
  • Choueiri TK. Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents. Clin Genitourin Cancer 2008;6:15-20
  • Wimazal F, Sperr WR, Kundi M, et al. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol 2008;19:970-6
  • George S, Bukowski RM. Biomarkers in clear cell renal cell carcinoma. Expert Rev Anticancer Ther 2007;7:1737-47
  • Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006;9:425-34
  • Choi SR, Pradhan A, Hammond NL, et al. Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors. J Med Chem 2007;50:3841-50
  • Deck LM, Royer RE, Chamblee BB, et al. Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite Plasmodium falciparum. J Med Chem 1998;41:3879-87

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.